$ZURA
Zura Bio Ltd

2024 Q1 Form 10-K Financial Statement

#000141057824000329 Filed on March 28, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.786M $3.907M $18.64M
YoY Change 68.52% 501.08% 595.49%
% of Gross Profit
Research & Development $3.593M $6.920M $44.00M
YoY Change -26.43%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $8.379M $10.83M $62.64M
YoY Change 8.55% 1565.69% 2237.24%
Operating Profit -$8.379M -$62.64M
YoY Change 8.55% 2241.48%
Interest Expense $609.0K $2.330M $4.302M
YoY Change 238.33% 76.52% -30.84%
% of Operating Profit
Other Income/Expense, Net $632.0K $24.00K -$2.227M
YoY Change -130.44% -135.78%
Pretax Income -$7.747M -$8.473M -$60.56M
YoY Change -20.91% -1364.63% -1806.0%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$7.747M -$6.278M -$69.24M
YoY Change -19.3% -1037.01% -2050.99%
Net Earnings / Revenue
Basic Earnings Per Share -$0.02 -$2.09
Diluted Earnings Per Share -$0.02 -$0.13 -$2.09
COMMON SHARES
Basic Shares Outstanding 43.59M 43.59M 33.06M
Diluted Shares Outstanding 46.91M 33.06M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $89.82M $99.81M $99.81M
YoY Change 104.13%
Cash & Equivalents $89.82M $99.81M $99.81M
Short-Term Investments
Other Short-Term Assets $657.0K $1.037M $1.037M
YoY Change 64.25%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $90.47M $100.8M $100.8M
YoY Change 103.84% 301040.74%
LONG-TERM ASSETS
Property, Plant & Equipment $9.000K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00
YoY Change
Total Long-Term Assets $9.000K $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL ASSETS
Total Short-Term Assets $90.47M $100.8M $100.8M
Total Long-Term Assets $9.000K $0.00 $0.00
Total Assets $90.48M $100.8M $100.8M
YoY Change 103.86% -28.74% -28.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.485M $20.19M $2.749M
YoY Change -38.36% 7056.71% 816.33%
Accrued Expenses $13.19M $111.0K $17.55M
YoY Change -90.01% 1495.73%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.67M $20.30M $20.30M
YoY Change 193.89% 1010.47% 1027.89%
LONG-TERM LIABILITIES
Long-Term Debt $1.596M $990.0K $990.0K
YoY Change 6.4%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $1.596M $990.0K $990.0K
YoY Change 6.4% -83.22% -83.22%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.67M $20.30M $20.30M
Total Long-Term Liabilities $1.596M $990.0K $990.0K
Total Liabilities $16.27M $41.51M $41.51M
YoY Change 149.16% 434.98% 432.22%
SHAREHOLDERS EQUITY
Retained Earnings -$111.2M -$103.5M
YoY Change 165.49% 1257.09%
Common Stock $4.000K $4.000K
YoY Change 33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $61.01M $59.33M $59.33M
YoY Change
Total Liabilities & Shareholders Equity $90.48M $100.8M $100.8M
YoY Change 103.86% -28.74% -28.73%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$7.747M -$6.278M -$69.24M
YoY Change -19.3% -1037.01% -2050.99%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$4.982M -$4.054M -$15.05M
YoY Change 52.96% 3278.33% 1305.56%
INVESTING ACTIVITIES
Capital Expenditures $7.000K $0.00 $8.000M
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$5.007M $0.00 -$8.000M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $132.5M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 3.000K 121.3M
YoY Change -100.0% -95.0% 34009.87%
NET CHANGE
Cash From Operating Activities -4.982M -4.054M -15.05M
Cash From Investing Activities -5.007M 0.000 -8.000M
Cash From Financing Activities 0.000 3.000K 121.3M
Net Change In Cash -9.989M -4.051M 98.24M
YoY Change -123.56% 6651.67% -13831.31%
FREE CASH FLOW
Cash From Operating Activities -$4.982M -$4.054M -$15.05M
Capital Expenditures $7.000K $0.00 $8.000M
Free Cash Flow -$4.989M -$4.054M -$23.05M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001855644
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022 zura Transfers Between Level2 And Level3
TransfersBetweenLevel2AndLevel3
0
CY2023 zura Transfers Between Level2 And Level3
TransfersBetweenLevel2AndLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q4 us-gaap Cash
Cash
1567000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1037000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
209000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
100843000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1776000
CY2022Q4 us-gaap Deferred Costs
DeferredCosts
3486000
CY2023Q4 us-gaap Assets
Assets
100843000
CY2022Q4 us-gaap Assets
Assets
5262000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
20302000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4428000
CY2022Q4 us-gaap Notes Payable To Bank Current
NotesPayableToBankCurrent
7756000
CY2022Q4 zura Research And Development License Consideration Liability
ResearchAndDevelopmentLicenseConsiderationLiability
2634000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20302000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14818000
CY2023Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent
SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent
990000
CY2023Q4 us-gaap Liabilities
Liabilities
21292000
CY2022Q4 us-gaap Liabilities
Liabilities
14818000
CY2023Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
18680000
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
13510415
CY2023Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
13510415
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43593678
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
279720
CY2023 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2023#FairValueAdjustmentOfWarrants
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-40598
CY2023 dei Entity Registrant Name
EntityRegistrantName
ZURA BIO LIMITED
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1725736
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
1489 W. Warm Springs Rd. #110
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Henderson
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89014
CY2023 dei City Area Code
CityAreaCode
702
CY2023 dei Local Phone Number
LocalPhoneNumber
757-6133
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
357468160
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43593678
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
true
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Trd Arr Ind Name
TrdArrIndName
Mr. Lisicki
CY2023Q4 ecd Trd Arr Ind Title
TrdArrIndTitle
President and Chief Operating Officer
CY2023Q4 ecd Trd Arr Adoption Date
TrdArrAdoptionDate
April 8, 2024
CY2023 dei Auditor Name
AuditorName
WithumSmith+Brown, PC
CY2023 dei Auditor Location
AuditorLocation
East Brunswick, New Jersey
CY2023 dei Auditor Firm
AuditorFirmId
100
CY2023Q4 us-gaap Cash
Cash
99806000
CY2022Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
10000000
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
13510415
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
12500000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43593678
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1884649
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
279720
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
162820000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103494000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32056000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
59330000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-32056000
CY2023Q4 us-gaap Minority Interest
MinorityInterest
1541000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
60871000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-32056000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
100843000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5262000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43999000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23689000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18639000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3473000
CY2023 us-gaap Operating Expenses
OperatingExpenses
62638000
us-gaap Operating Expenses
OperatingExpenses
27162000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-62638000
us-gaap Operating Income Loss
OperatingIncomeLoss
-27162000
CY2023 zura Other Income Expense Net
OtherIncomeExpenseNet
17000
zura Other Income Expense Net
OtherIncomeExpenseNet
-23000
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
2186000
us-gaap Investment Income Interest
InvestmentIncomeInterest
8000
CY2023 us-gaap Investment Income Dividend
InvestmentIncomeDividend
1392000
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-724000
CY2023 zura Fair Value Adjustment Of Note Payable
FairValueAdjustmentOfNotePayable
2244000
zura Fair Value Adjustment Of Note Payable
FairValueAdjustmentOfNotePayable
156000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2075000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-171000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-60563000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27333000
CY2023 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-60563000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-27333000
CY2023 us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
-203000
us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
-1595000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-60360000
us-gaap Net Income Loss
NetIncomeLoss
-25738000
CY2023 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
7220000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
6652000
CY2023 zura Deemed Contribution From Redeemable Noncontrolling Interest
DeemedContributionFromRedeemableNoncontrollingInterest
9212000
CY2023 zura Deemed Dividend To Redeemable Noncontrolling Interest
DeemedDividendToRedeemableNoncontrollingInterest
10875000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-69243000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-32390000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.09
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-141.97
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-141.97
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33064036
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33064036
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
228148
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
228148
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-32056000
CY2023 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
14686000
CY2023 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
4000000.0
CY2023 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
48351000
CY2023 zura Stock Issued During Period Value Research And Development License Consideration Liability
StockIssuedDuringPeriodValueResearchAndDevelopmentLicenseConsiderationLiability
4488000
CY2023 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2001000
CY2023 zura Stock Issued Transaction Costs
StockIssuedTransactionCosts
9800000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13059000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-60360000
CY2023 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
7220000
CY2023 zura Value Of Issued Call Right
ValueOfIssuedCallRight
1541000
CY2023 zura Adjustment Of Deemed Contribution From Redeemable Noncontrolling Interest
AdjustmentOfDeemedContributionFromRedeemableNoncontrollingInterest
9212000
CY2023 zura Adjustment Of Deemed Dividend To Redeemable Noncontrolling Interest
AdjustmentOfDeemedDividendToRedeemableNoncontrollingInterest
10875000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
60871000
CY2022Q1 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
0
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
334000
us-gaap Net Income Loss
NetIncomeLoss
-25738000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
6652000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-32056000
CY2023Q4 zura Exchange Ratio For Ordinary Shares Pursuant To Business Combination
ExchangeRatioForOrdinarySharesPursuantToBusinessCombination
108.083
CY2023 us-gaap Profit Loss
ProfitLoss
-60563000
us-gaap Profit Loss
ProfitLoss
-27333000
CY2023 zura Research And Development Expense On Acquired License
ResearchAndDevelopmentExpenseOnAcquiredLicense
27381000
zura Research And Development Expense On Acquired License
ResearchAndDevelopmentExpenseOnAcquiredLicense
21892000
CY2023 zura Anti Dilution Share Issuance Compensation
AntiDilutionShareIssuanceCompensation
2186000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
7469000
us-gaap Share Based Compensation
ShareBasedCompensation
334000
CY2023 zura Fair Value Adjustment Of Note Payable
FairValueAdjustmentOfNotePayable
2244000
zura Fair Value Adjustment Of Note Payable
FairValueAdjustmentOfNotePayable
156000
CY2023 zura Fair Value Adjustment Of Share Based Payment Liability
FairValueAdjustmentOfShareBasedPaymentLiability
1854000
zura Fair Value Adjustment Of Share Based Payment Liability
FairValueAdjustmentOfShareBasedPaymentLiability
185000
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-724000
CY2023 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
17000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-23000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
828000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
209000
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5944000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3750000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15054000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1202000
CY2023 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
8000000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
12000000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12000000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
10000000
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
4200000
CY2023 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
59724000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
56683000
CY2023 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
16070000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
7600000
CY2023 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
10000000
CY2023 zura Payment Of Deferred Transaction Costs
PaymentOfDeferredTransactionCosts
1184000
zura Payment Of Deferred Transaction Costs
PaymentOfDeferredTransactionCosts
2831000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
121293000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14769000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
98239000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1567000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1567000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
99806000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1567000
us-gaap Stock Issued1
StockIssued1
2500000
CY2023 zura Conversion Of Series One Convertible Preferred Shares For Ordinary Shares
ConversionOfSeriesOneConvertiblePreferredSharesForOrdinaryShares
14686000
CY2023 zura Accrued License Consideration
AccruedLicenseConsideration
10000000
CY2023 zura Accretion Of Redeemable Noncontrolling Interest To Redemption Value
AccretionOfRedeemableNoncontrollingInterestToRedemptionValue
7220000
zura Accretion Of Redeemable Noncontrolling Interest To Redemption Value
AccretionOfRedeemableNoncontrollingInterestToRedemptionValue
6652000
CY2023 zura Adjustment Of Deemed Contribution From Redeemable Noncontrolling Interest
AdjustmentOfDeemedContributionFromRedeemableNoncontrollingInterest
9212000
CY2023 zura Adjustment Of Deemed Dividend To Redeemable Noncontrolling Interest
AdjustmentOfDeemedDividendToRedeemableNoncontrollingInterest
10875000
CY2023 zura Issuance Of Shares For Consideration License
IssuanceOfSharesForConsiderationLicense
7840000
CY2023 zura Share Based Equity Issuance Costs
ShareBasedEquityIssuanceCosts
5590000
CY2023 zura Settlement Of Research And Development License Consideration Liability
SettlementOfResearchAndDevelopmentLicenseConsiderationLiability
4488000
zura Transaction Costs Include In Accounts Payable
TransactionCostsIncludeInAccountsPayable
655000
CY2023 zura Reclassification Of Deferred Transaction Costs To Additional Paid In Capital
ReclassificationOfDeferredTransactionCostsToAdditionalPaidInCapital
4015000
CY2023 zura Assumption Of Public And Private Placement Warrants In Connection With Business Combination
AssumptionOfPublicAndPrivatePlacementWarrantsInConnectionWithBusinessCombination
3715000
CY2023 zura Reclassification Of Public Warrant Liability To Equity
ReclassificationOfPublicWarrantLiabilityToEquity
2001000
CY2023 zura Issuance Of Call Right To Noncontrolling Interest
IssuanceOfCallRightToNoncontrollingInterest
1541000
zura Temporary Equity Subsidiary Stock Issued During Period Value License
TemporaryEquitySubsidiaryStockIssuedDuringPeriodValueLicense
4943000
zura Research And Development Consideration Liability For License
ResearchAndDevelopmentConsiderationLiabilityForLicense
2449000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103500000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32100000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-60400000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-25700000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
99800000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
56700000
CY2023Q2 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
75800000
CY2023Q4 us-gaap Deferred Costs
DeferredCosts
0
CY2022Q4 us-gaap Deferred Costs
DeferredCosts
3500000
CY2023Q4 zura Exchange Ratio For Ordinary Shares Pursuant To Business Combination
ExchangeRatioForOrdinarySharesPursuantToBusinessCombination
108.083
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22644072
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13893786
CY2023Q1 zura Number Of Ordinary Shares Issued And Outstanding Immediately Following Business Combination
NumberOfOrdinarySharesIssuedAndOutstandingImmediatelyFollowingBusinessCombination
27052155
CY2023Q1 zura Percentage On Outstanding Shares
PercentageOnOutstandingShares
1.000
CY2022Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
10390000
CY2022 zura Fair Value Liability Level1 To Level2 Transfers Amount
FairValueLiabilityLevel1ToLevel2TransfersAmount
0
CY2023 zura Fair Value Liability Level1 To Level2 Transfers Amount
FairValueLiabilityLevel1ToLevel2TransfersAmount
0
CY2023 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
10000000.0
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
7756000
CY2023 zura Fair Value Adjustment Of Note Payable
FairValueAdjustmentOfNotePayable
2244000
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
-10000000
CY2023 zura Fair Value Adjustment Of Note Payable
FairValueAdjustmentOfNotePayable
2200000
CY2022 zura Fair Value Adjustment Of Note Payable
FairValueAdjustmentOfNotePayable
200000
CY2023 zura Gain Or Loss On Remeasurement Of Research And Development License Consideration Liability
GainOrLossOnRemeasurementOfResearchAndDevelopmentLicenseConsiderationLiability
1900000
CY2022 zura Gain Or Loss On Remeasurement Of Research And Development License Consideration Liability
GainOrLossOnRemeasurementOfResearchAndDevelopmentLicenseConsiderationLiability
200000
CY2023 zura Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Assumptions
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAssumptions
1714000
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-724000
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
990000
CY2023Q4 zura Accrued2023 Lilly License Costs
Accrued2023LillyLicenseCosts
10000000
CY2023Q4 zura Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
6091000
CY2022Q4 zura Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
490000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2749000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2010000
CY2023Q4 zura Accrued Bonus Cost Current
AccruedBonusCostCurrent
1201000
CY2022Q4 zura Accrued Bonus Cost Current
AccruedBonusCostCurrent
141000
CY2023Q4 zura Accrued Consulting Costs Current
AccruedConsultingCostsCurrent
150000
CY2022Q4 zura Accrued Consulting Costs Current
AccruedConsultingCostsCurrent
451000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
111000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
681000
CY2022Q4 zura Accrued Offering Costs Current
AccruedOfferingCostsCurrent
655000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
20302000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4428000
CY2023Q4 us-gaap Minority Interest
MinorityInterest
1500000
CY2022Q4 us-gaap Minority Interest
MinorityInterest
0
CY2023Q3 zura Payments Of Non Refundable License Fee
PaymentsOfNonRefundableLicenseFee
150000
CY2023Q1 us-gaap Preferred Stock Convertible Shares Issuable
PreferredStockConvertibleSharesIssuable
267939
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 zura Exchange Ratio For Ordinary Shares Pursuant To Business Combination
ExchangeRatioForOrdinarySharesPursuantToBusinessCombination
108.083
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 zura Temporary Equity Minimum Gross Aggregate Subscription Of Ordinary Shares Required For Conversion Of Temporary Equity
TemporaryEquityMinimumGrossAggregateSubscriptionOfOrdinarySharesRequiredForConversionOfTemporaryEquity
50000000.0
CY2022Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0
CY2022Q1 us-gaap Temporary Equity Liquidation Preference Per Share
TemporaryEquityLiquidationPreferencePerShare
131
CY2022Q1 zura Temporary Equity Number Of Votes Per Share
TemporaryEquityNumberOfVotesPerShare
1
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
34199249
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1309000
CY2023Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
9496000
CY2023Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2023Q1 zura Exchange Ratio For Ordinary Shares Pursuant To Business Combination
ExchangeRatioForOrdinarySharesPursuantToBusinessCombination
108.083
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9655000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
334000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-36842000
us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-15253000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-23721000
us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-12080000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-60563000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27333000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
6300000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
4200000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
100000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.017
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.039
CY2023 zura Effective Income Tax Rate Reconciliation Impact Of Foreign Earnings Percent
EffectiveIncomeTaxRateReconciliationImpactOfForeignEarningsPercent
-0.003
CY2022 zura Effective Income Tax Rate Reconciliation Impact Of Foreign Earnings Percent
EffectiveIncomeTaxRateReconciliationImpactOfForeignEarningsPercent
-0.012
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.189
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.235
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.006
CY2023 zura Effective Income Tax Rate Reconciliation Permanent Differences Percent
EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
-0.006
CY2022 zura Effective Income Tax Rate Reconciliation Permanent Differences Percent
EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
-0.002
CY2023 zura Effective Income Tax Rate Reconciliation Change In Deferred Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxRate
0.011
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
6947000
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
5020000
CY2023Q4 zura Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
619000
CY2022Q4 zura Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
51000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
831000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
39000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
17893000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
6419000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
17893000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
6419000
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
11500000
CY2023Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
18700000
CY2022Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
10000000.0

Files In Submission

Name View Source Status
0001410578-24-000329-index-headers.html Edgar Link pending
0001410578-24-000329-index.html Edgar Link pending
0001410578-24-000329.txt Edgar Link pending
0001410578-24-000329-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zura-20231231.xsd Edgar Link pending
zura-20231231x10k.htm Edgar Link pending
zura-20231231x10k001.jpg Edgar Link pending
zura-20231231x10k002.jpg Edgar Link pending
zura-20231231x10k003.jpg Edgar Link pending
zura-20231231x10k004.jpg Edgar Link pending
zura-20231231x10k005.jpg Edgar Link pending
zura-20231231x10k006.jpg Edgar Link pending
zura-20231231xex31d1.htm Edgar Link pending
zura-20231231xex31d2.htm Edgar Link pending
zura-20231231xex32d1.htm Edgar Link pending
zura-20231231xex32d2.htm Edgar Link pending
zura-20231231xex4d2.htm Edgar Link pending
zura-20231231xex97.htm Edgar Link pending
zura-20231231xex97g001.jpg Edgar Link pending
zura-20231231xex97g002.jpg Edgar Link pending
zura-20231231xex97g003.jpg Edgar Link pending
zura-20231231xex97g004.jpg Edgar Link pending
zura-20231231xex97g005.jpg Edgar Link pending
zura-20231231xex97g006.jpg Edgar Link pending
zura-20231231_def.xml Edgar Link unprocessable
zura-20231231_lab.xml Edgar Link unprocessable
zura-20231231_pre.xml Edgar Link unprocessable
zura-20231231_cal.xml Edgar Link unprocessable
zura-20231231x10k_htm.xml Edgar Link completed